<info type="DiseaseOrPhenotypicFeature">congestive heart failure</info> in patients who developed <info type="ChemicalEntity">anthracycline</info>-related <info type="DiseaseOrPhenotypicFeature">congestive heart failure</info> after <info type="DiseaseOrPhenotypicFeature">childhood cancer</info>.

BACKGROUND: Exposure to <info type="ChemicalEntity">anthracyclines</info> as part of <info type="DiseaseOrPhenotypicFeature">cancer therapy</info> has been associated with the development of <info type="DiseaseOrPhenotypicFeature">congestive heart failure</info> (<info type="DiseaseOrPhenotypicFeature">CHF</info>). The potential role of <info type="DiseaseOrPhenotypicFeature">genetic risk factors</info> in <info type="ChemicalEntity">anthracycline</info>-related <info type="DiseaseOrPhenotypicFeature">CHF</info> remains to be defined. Thus, in this study, the authors examined whether common <info type="SequenceVariant">polymorphisms</info> in candidate <info type="GeneOrGeneProduct">genes</info> involved in the pharmacodynamics of <info type="ChemicalEntity">anthracyclines</info> (in particular, the <info type="GeneOrGeneProduct">nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene</info> <info type="GeneOrGeneProduct">NQO1</info> and the <info type="GeneOrGeneProduct">carbonyl reductase 3 gene</info> <info type="GeneOrGeneProduct">CBR3</info>) had an impact on the risk of <info type="ChemicalEntity">anthracycline</info>-related <info type="DiseaseOrPhenotypicFeature">CHF</info>. METHODS: A nested case-control study was conducted within a cohort of 1979 patients enrolled in the <info type="DiseaseOrPhenotypicFeature">Childhood Cancer Survivor Study</info> who received treatment with <info type="ChemicalEntity">anthracyclines</info> and had available <info type="GeneOrGeneProduct">DNA</info>. Thirty patients with <info type="DiseaseOrPhenotypicFeature">CHF</info> (cases) and 115 matched controls were genotyped for <info type="SequenceVariant">polymorphisms</info> in <info type="GeneOrGeneProduct">NQO1</info> (<info type="SequenceVariant">NQO1*2</info>) and <info type="GeneOrGeneProduct">CBR3</info> (the <info type="GeneOrGeneProduct">CBR3</info> <info type="SequenceVariant">valine [V] to methionine [M] substitution</info> at position 244 [<info type="SequenceVariant">V244M</info>]). Enzyme activity assays with recombinant <info type="GeneOrGeneProduct">CBR3</info> isoforms (<info type="GeneOrGeneProduct">CBR3</info> <info type="SequenceVariant">V244</info> and <info type="GeneOrGeneProduct">CBR3</info> <info type="SequenceVariant">M244</info>) and the <info type="ChemicalEntity">anthracycline</info> substrate <info type="ChemicalEntity">doxorubicin</info> were used to investigate the functional impact of the <info type="SequenceVariant">CBR3 V244M</info> <info type="SequenceVariant">polymorphism</info>. RESULTS: Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic <info type="SequenceVariant">polymorphisms</info> (<info type="SequenceVariant">NQO1*2</info> and <info type="SequenceVariant">CBR3 V244M</info>) and the risk of <info type="DiseaseOrPhenotypicFeature">CHF</info>. Analyses indicated no association between the <info type="SequenceVariant">NQO1*2</info> <info type="SequenceVariant">polymorphism</info> and the risk of <info type="ChemicalEntity">anthracycline</info>-related <info type="DiseaseOrPhenotypicFeature">CHF</info> (odds ratio [OR], 1.04; P=.97). There was a trend toward an association between the <info type="SequenceVariant">CBR3 V244M</info> <info type="SequenceVariant">polymorphism</info> and the risk of <info type="DiseaseOrPhenotypicFeature">CHF</info> (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A). In line, recombinant <info type="GeneOrGeneProduct">CBR3 V244</info> (G allele) synthesized 2.6-fold more cardiotoxic <info type="ChemicalEntity">doxorubicinol</info> per unit of time than <info type="GeneOrGeneProduct">CBR3 M244</info> (A allele; <info type="GeneOrGeneProduct">CBR3 V244</info> [8.26+/-3.57 nmol/hour.mg] vs <info type="GeneOrGeneProduct">CBR3 M244</info> [3.22+/-0.67 nmol/hour.mg]; P=.01). CONCLUSIONS: The functional <info type="GeneOrGeneProduct">CBR3 V244M</info> <info type="SequenceVariant">polymorphism</info> may have an impact on the risk of <info type="ChemicalEntity">anthracycline</info>-related <info type="DiseaseOrPhenotypicFeature">CHF</info> among <info type="DiseaseOrPhenotypicFeature">childhood cancer</info> survivors by modulating the intracardiac formation of cardiotoxic <info type="ChemicalEntity">anthracycline</info> alcohol metabolites. Larger confirmatory case-control studies are warranted.